ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Portland, OR, USA:

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 2

AbbVie
AbbVie

Portland, Oregon, United States and 39 other locations

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Portland, Oregon, United States and 37 other locations

is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: CTX120

Phase 1

CRISPR Therapeutics

Portland, Oregon, United States and 9 other locations

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

Portland, Oregon, United States and 35 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Portland, Oregon, United States and 156 other locations

with BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study ...

Active, not recruiting
Multiple Myeloma
Drug: CC-99712
Drug: BMS-986405

Phase 1

Celgene
Celgene

Portland, Oregon, United States and 19 other locations

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Ani...

Enrolling
Multiple Myeloma
Biological: anitocabtagene-autoleucel

Phase 2

Gilead Sciences
Gilead Sciences

Portland, Oregon, United States and 19 other locations

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Enrolling
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Portland, Oregon, United States and 25 other locations

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

Portland, Oregon, United States and 256 other locations

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Salem, Oregon, United States and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems